Pancreatic ductal adenocarcinoma and transcription factors: Role of c-Myc

被引:46
|
作者
Skoudy A. [1 ]
Hernández-Muñoz I. [1 ]
Navarro P. [1 ]
机构
[1] Cancer Research Programme, IMIM (Institut de Recerca Hospital Del Mar), Barcelona 08003
关键词
c-Myc; Ela-myc transgenic mouse; Pancreatic development; Pancreatic ductal adenocarcinoma; Transcription factor;
D O I
10.1007/s12029-011-9258-0
中图分类号
学科分类号
摘要
Introduction: Deregulated expression/activation of transcription factors is a key event in the establishment and progression of human cancer. Furthermore, most oncogenic signaling pathways converge on sets of transcription factors that ultimately control gene expression patterns resulting in cancer development, progression, and metastasis. Methods: Ductal pancreatic adenocarcinoma (PDA) is the main type of pancreatic cancer and the fourth leading cause of cancer mortality in the Western world. The early stage of the disease is characterized by pancreatic intraepithelial neoplasia lesions bearing mutations in the K-RAS proto-oncogene, which progress to malignant PDA by accumulating additional mutations in the tumor suppressor gene CDKN2A (p16) and in SMAD4 and TP53 transcription factors. The involvement of other signaling pathways in PDA development and progression is an active area of research which may help to clarify the critical steps of this devastating disease. Results: In this regard, several in vitro and in vivo data have demonstrated the contribution of the transcription factor c-Myc to pancreatic carcinogenesis although the molecular mechanisms are poorly understood. c-Myc is a proto-oncogene which has a pivotal function in growth control, differentiation and apoptosis and is known to act as a downstream transcriptional effector of many signaling pathways involved in these processes. It is regulated at multiple levels and its abnormal expression contributes to the genesis of many human tumors. Conclusions: This review focuses on the role of c-Myc in pancreatic embryonic development and homeostasis as well as its involvement on pancreatic tumorigenesis. Evidences showing that c-Myc function is highly dose and cell context dependent, together with its recently demonstrated ability to reprogram somatic cells towards a pluripotent stem cell-like state, indicate that the role of c-Myc in pancreas pathophysiology might have been previously underscored. © 2011 Springer Science+Business Media, LLC.
引用
收藏
页码:76 / 84
页数:8
相关论文
共 50 条
  • [1] High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma
    Li, Ke
    Yang, Jiali
    Chen, Jiafei
    Shi, Yanshu
    Zhang, Zhuoli
    Chen, Wei
    ONCOLOGY LETTERS, 2020, 19 (02) : 1584 - 1592
  • [2] A novel mouse model for the study of c-MYC during initiation and progression of pancreatic ductal adenocarcinoma
    Lin, Wan-Chi
    Zhang, Qian
    Opaysky, Rene
    DiMaio, Dominick J.
    Felsher, Dean W.
    Batra, Surinder K.
    Hollingsworth, Michael A.
    Wagner, Kay-Uwe
    CANCER RESEARCH, 2011, 71
  • [3] Docosahexaenoic Acid Inhibits Cell Proliferation through a Suppression of c-Myc Protein in Pancreatic Ductal Adenocarcinoma Cells
    Syu, Jia-Ning
    Lee, Der-Yen
    Hung, Hung-Chang
    Li, Chia-Ying
    Lin, Hung-Yu
    Chiang, En-Pei Isabel
    Chen, Yi-Heng
    Huang, Shu-Ming
    Tang, Feng-Yao
    ANTIOXIDANTS, 2021, 10 (11)
  • [4] Inhibition of c-Myc by 10058-F4 induces growth arrest and chemosensitivity in pancreatic ductal adenocarcinoma
    Zhang, Meng
    Fan, Hai-Yan
    Li, Sheng-Chao
    BIOMEDICINE & PHARMACOTHERAPY, 2015, 73 : 123 - 128
  • [5] FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma
    Bo Wang
    Ping Fan
    Jingyuan Zhao
    Heyu Wu
    Xin Jin
    Heshui Wu
    Journal of Experimental & Clinical Cancer Research, 37
  • [6] LncRNA CCAT1 participates in pancreatic ductal adenocarcinoma progression by forming a positive feedback loop with c-Myc
    Cheng, Chundong
    Liu, Zonglin
    Liu, Danxi
    Chen, Hua
    Wang, Yongwei
    Sun, Bei
    CARCINOGENESIS, 2024, 45 (1-2) : 69 - 82
  • [7] FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma
    Wang, Bo
    Fan, Ping
    Zhao, Jingyuan
    Wu, Heyu
    Jin, Xin
    Wu, Heshui
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [8] Transcription factors as drivers of distinct pancreatic ductal adenocarcinoma (PDAC) programmes: a role for HNF4A
    Diaferia, Giuseppe Riccardo
    Natoli, Gioacchino
    GUT, 2021, 70 (05) : 816 - 817
  • [9] Mechanism of c-Myc autoregulation: c-Myc activates the transcription of Mxi which downregulates c-Myc expression.
    Mattioli, M
    Wu, KJ
    Dalla-Favera, R
    BLOOD, 2000, 96 (11) : 701A - 701A
  • [10] Predictive factors in pancreatic ductal adenocarcinoma: Role of the inflammatory response
    Tingstedt, Bobby
    Johansson, Patrik
    Andersson, Bodil
    Andersson, Roland
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2007, 42 (06) : 754 - 759